CMN 577 Exam Final Questions and Answers with Verified Solutions |
Latest 2026 Update
Q: Which of the following patients is at highest risk for developing a post-surgical
DVT/VTE?
Answer:
A. A 47-year-old female undergoing a right total knee replacement, BMI of 35,
current smoker and on oral estrogen for menopausal symptoms. B. An 18-year-old
female, nonsmoker, BMI of 21 undergoing extraction of wisdom teeth with Twirla
patch (levonorgesterel/ethinyl estradiol transdermal) for birth control. C. A
48-year-old male, smoker but otherwise healthy for first routine colonoscopy
screening. D. A 51-year-old male, non-smoker, with HTN and a BMI of 28
undergoing turbinate reduction as an outpatient. On lisinopril 10mg daily for HTN.
A. A 47-year-old female undergoing a right total knee replacement, BMI of 35,
current smoker and on oral estrogen for menopausal symptoms.
,CMN 577 Exam Final Questions and Answers with Verified Solutions |
Latest 2026 Update
Q: Your patient underwent a knee replacement surgery and subsequently has
formed a DVT. He
Answer:
has no risk factors other than history of surgery. The NP would anticipate the length
of his
anticoagulant treatment course to be:
a. 3 months
b. 3-6 months
c. 1 year
d. Indefinite a. 3 months
Q: Which of the following is a true statement regarding Direct-Acting Oral
Anticoagulants (DOAC's)?
Answer:
a. A patient taking a DOAC medication should monitor their diet closely to ensure
they limit their vitamin K intake b. A patient with renal disease may require renal
dosing adjustment c. DOAC medications can have an unpredictable effect and
require laboratory monitoring d. The effects of DOAC medications are easily
monitored b. A patient with renal disease may require renal dosing adjustment
,CMN 577 Exam Final Questions and Answers with Verified Solutions |
Latest 2026 Update
Q: A Patient is diagnosed with a DVT of the lower extremity. She is started on
Rivaroxaban
Answer:
(Xarelto). The patient asks the APRN how often she will have to come get blood
work to check
her PT/INR. She APRNcorrectly responds:
A. We will have you return monthly to draw a PT/INR to measure the anticoagulant
effect of
the medication.
B. Routine monitoring is not recommended for patients taking Rivaroxaban
(Xarelto).
C. We will have you come in randomly to spot-check your PT/INR to make sure
your medication
is therapeutic.
D. We will have you return in 3 months to check your PT/INR to make sure
Rivaroxaban
(Xarelto) is therapeutic. B. Routine monitoring is not recommended for patients
taking
Rivaroxaban (Xarelto).
, CMN 577 Exam Final Questions and Answers with Verified Solutions |
Latest 2026 Update
Q: There is a 49 year old male in your office with a newly diagnosed DVT. He is
going to be started
Answer:
on Eliquis (apixaban). All of the following are true regarding this direct-acting oral
anticoagulant
EXCEPT
a. It does not require monitoring of labs
b. It is metabolized in the liver
c. It has a lower bleeding risk than LMWH and warfarin
d. It has a reversal agent available b. It is metabolized in the liver
Latest 2026 Update
Q: Which of the following patients is at highest risk for developing a post-surgical
DVT/VTE?
Answer:
A. A 47-year-old female undergoing a right total knee replacement, BMI of 35,
current smoker and on oral estrogen for menopausal symptoms. B. An 18-year-old
female, nonsmoker, BMI of 21 undergoing extraction of wisdom teeth with Twirla
patch (levonorgesterel/ethinyl estradiol transdermal) for birth control. C. A
48-year-old male, smoker but otherwise healthy for first routine colonoscopy
screening. D. A 51-year-old male, non-smoker, with HTN and a BMI of 28
undergoing turbinate reduction as an outpatient. On lisinopril 10mg daily for HTN.
A. A 47-year-old female undergoing a right total knee replacement, BMI of 35,
current smoker and on oral estrogen for menopausal symptoms.
,CMN 577 Exam Final Questions and Answers with Verified Solutions |
Latest 2026 Update
Q: Your patient underwent a knee replacement surgery and subsequently has
formed a DVT. He
Answer:
has no risk factors other than history of surgery. The NP would anticipate the length
of his
anticoagulant treatment course to be:
a. 3 months
b. 3-6 months
c. 1 year
d. Indefinite a. 3 months
Q: Which of the following is a true statement regarding Direct-Acting Oral
Anticoagulants (DOAC's)?
Answer:
a. A patient taking a DOAC medication should monitor their diet closely to ensure
they limit their vitamin K intake b. A patient with renal disease may require renal
dosing adjustment c. DOAC medications can have an unpredictable effect and
require laboratory monitoring d. The effects of DOAC medications are easily
monitored b. A patient with renal disease may require renal dosing adjustment
,CMN 577 Exam Final Questions and Answers with Verified Solutions |
Latest 2026 Update
Q: A Patient is diagnosed with a DVT of the lower extremity. She is started on
Rivaroxaban
Answer:
(Xarelto). The patient asks the APRN how often she will have to come get blood
work to check
her PT/INR. She APRNcorrectly responds:
A. We will have you return monthly to draw a PT/INR to measure the anticoagulant
effect of
the medication.
B. Routine monitoring is not recommended for patients taking Rivaroxaban
(Xarelto).
C. We will have you come in randomly to spot-check your PT/INR to make sure
your medication
is therapeutic.
D. We will have you return in 3 months to check your PT/INR to make sure
Rivaroxaban
(Xarelto) is therapeutic. B. Routine monitoring is not recommended for patients
taking
Rivaroxaban (Xarelto).
, CMN 577 Exam Final Questions and Answers with Verified Solutions |
Latest 2026 Update
Q: There is a 49 year old male in your office with a newly diagnosed DVT. He is
going to be started
Answer:
on Eliquis (apixaban). All of the following are true regarding this direct-acting oral
anticoagulant
EXCEPT
a. It does not require monitoring of labs
b. It is metabolized in the liver
c. It has a lower bleeding risk than LMWH and warfarin
d. It has a reversal agent available b. It is metabolized in the liver
